Patients with cervical myelopathy caused by narrowing of the spinal canal are at higher risks of acute spinal cord injury if involved in accidents. Tumors
Irregular growths of soft tissue will cause inflammation. Growth of tissue into the canal pressing on nerves, the sac of nerves, or the spinal cord. Diagnosis
The diagnosis of spinal stenosis involves a complete evaluation of the spine. The process usually begins with a medical history and physical examination. X-ray and MRI scans are typically used to determine the extent and location of the nerve compression. Medical history
The medical history is the most important aspect of the examination as it will tell the physician about subjective symptoms, possible causes for spinal stenosis, and other possible causes of back pain. Physical examination
The physical examination of a patient with spinal stenosis will give the physician information about exactly where nerve compression is occurring. Some important factors that should be investigated are any areas of sensory abnormalities, numbness, irregular reflexes, and any muscular weakness. MRI
MRI has become the most frequently used study to diagnose spinal stenosis. The MRI uses electromagnetic signals to produce images of the spine. MRIs are helpful because they show more structures, including nerves, muscles, and ligaments, than seen on X-rays or CT scans. MRIs are helpful at showing exactly what is causing spinal nerve compression. Myelography
In CT myelography, spinal tap is performed in the low back with dye injected into the spinal fluid. X-rays are performed followed by a CT scan of the spine to help see narrowing of the spinal canal.
Hence it is not surprising that OWT therapy has not become popular and is very sparingly used across the globe. References
External links
"Levothyroxine". Drug Information Portal. U.S. National Library of Medicine. "Levothyroxine sodium". Drug Information Portal. U.S. National Library of Medicine. "Real-world Evidence from a Narrow Therapeutic Index Product (Levothyroxine) Reflects the Therapeutic Equivalence of Generic Drug Products". U.S. Food and Drug Administration (FDA). 19 November 2020.